Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.
TNBC recurrence hazard curve
Long-term follow-up of TNBC cohorts demonstrates a characteristic hazard curve[1]A:
- Years 1–3: peak recurrence hazard, with annual recurrence rate of 5–10% in untreated or residual-disease patients, lower with modern systemic therapy
- Years 3–5: declining hazard, transitioning from peak to plateau
- Years 5–10: low and declining hazard; substantially less recurrence risk than years 1–3
- Beyond 10 years: very low recurrence rate; substantial differentiation from HR+ disease, which retains 1–2% annual recurrence indefinitely
The hazard pattern has clinical implications: surveillance intensity should be highest in years 1–3 when recurrence risk is concentrated. After 5 years, TNBC patients with no recurrence have a relatively favorable long-term prognosis (better than HR+ disease at the equivalent time point).
Patterns of recurrence
TNBC recurrence patterns differ from HR+ disease:
- Visceral predominance: lung, liver, CNS predominate over bone (bone is more common in HR+ disease)
- CNS metastasis: ~30% lifetime incidence in metastatic TNBC; brain metastasis is a distinctive concern requiring active screening attention (see brain metastases synthesis)
- Local recurrence: chest wall and regional lymph node recurrence; appropriate locoregional surveillance is essential
- Contralateral breast cancer: slightly elevated risk, especially in BRCA1/2 carriers (see surgical considerations for contralateral mastectomy discussion)
- Second primary cancers: small risk of second primary breast or non-breast cancers; ovarian cancer screening relevant in BRCA mutation carriers
Guideline-recommended surveillance
NCCN and ASCO guidelines for breast cancer surveillance after curative treatment are intentionally minimalist:
- History and physical exam: every 3–6 months for the first 3 years, then every 6–12 months for years 4–5, then annually
- Mammography: annually starting 6–12 months after radiation completion; bilateral for lumpectomy, contralateral for mastectomy
- Breast MRI: annually for patients with hereditary risk (BRCA1/2 carriers and others with high lifetime risk)
- No routine systemic imaging (no chest CT, no abdominal CT, no bone scan, no FDG-PET) for asymptomatic surveillance — this is the strongest current recommendation, supported by older randomized evidence showing no survival benefit from intensive surveillance vs symptom-triggered workup
- No routine tumor markers (no CA 15-3, CA 27-29, CEA) for asymptomatic surveillance
- Genetic counseling and testing if not previously completed
The rationale for minimalist surveillance is the historical evidence that earlier detection of asymptomatic recurrence does not improve overall survival in breast cancer, even when imaging finds metastatic disease earlier than symptoms would have. This rationale predates modern targeted therapy for metastatic TNBC; the question of whether modern therapy changes the calculus is being re-examined.
Symptom-triggered evaluation
Patients should be counseled to report symptoms that might represent recurrence:
- New or progressive bone pain
- Cough, shortness of breath, hemoptysis
- Headache, focal neurological symptoms, seizure (CNS concern given TNBC predisposition)
- Right upper quadrant pain or jaundice (liver)
- Unexplained weight loss, persistent fatigue
- Lymphadenopathy, chest wall masses, scar changes
Symptom-triggered workup with appropriate imaging (CT, MRI, PET-CT, bone scan as indicated) and biopsy is the standard approach. Time-to-diagnosis with symptom-triggered approach is days to weeks for most patients.
Circulating tumor DNA (ctDNA) and minimal residual disease
Tumor-informed ctDNA assays (typically panel-based detection of tumor-specific mutations in plasma) have emerged as sensitive tools for minimal residual disease (MRD) monitoring. In TNBC specifically:
- Magbanua 2021 (I-SPY 2) and others demonstrated that detection of ctDNA post-neoadjuvant treatment identifies a high-risk subset with substantially worse distant recurrence-free survival[2]A.
- ctDNA detection precedes clinical recurrence by months in many cases (median lead time ~6–12 months in early studies; varies by assay sensitivity and clinical setting).
- Tumor-informed assays (Signatera, RaDaR, others) typically have higher sensitivity in MRD context than tumor-naive panels.
- Specificity is high: false-positive rates are low, particularly for tumor-informed assays.
- Sensitivity is incomplete: detection of low-volume disease (CNS metastases, oligometastatic) is less reliable than detection of higher-burden disease.
ctDNA-guided intervention trials
The clinical question shifting practice is whether ctDNA-guided intervention — treatment intensification at ctDNA detection before clinical recurrence — improves outcomes. Multiple trials are addressing this:
- c-TRAK TN — tested ctDNA-triggered pembrolizumab in TNBC with ctDNA detection in residual-disease setting; showed feasibility and some efficacy signal in early reports
- LEADER trial (HR+) — ctDNA-triggered intervention with palbociclib; informs methodology applicable to TNBC
- ASCENT-05 — testing sacituzumab govitecan in residual-disease TNBC; not strictly ctDNA-guided but addresses similar high-risk subset
- Multiple emerging trials — testing checkpoint inhibitors, ADCs, PARP inhibitors triggered by ctDNA positivity
Open methodological questions: optimal ctDNA assay platform, lead-time considerations, treatment selection at MRD positivity, duration of intervention, and randomization design.
Imaging considerations
Despite the minimalist surveillance guideline, certain imaging contexts are appropriate:
- Mammography: annual surveillance of remaining breast tissue
- Breast MRI: for high-risk patients (BRCA carriers, prior locally advanced disease, dense breasts)
- Chest CT and brain MRI: in symptom-triggered workup; not routine
- PET-CT: for restaging at recurrence or in workup of suspicious findings; not routine surveillance
- Bone scan: for symptom-triggered workup or restaging
- Pelvic imaging in BRCA carriers: some experts include surveillance for ovarian cancer in BRCA mutation carriers who have not undergone risk-reducing salpingo-oophorectomy
Surveillance duration and de-escalation
Given TNBC's recurrence hazard pattern:
- Surveillance intensity can be reduced after 5 years given low residual recurrence risk
- Most patients who remain disease-free at 10 years are unlikely to recur; transition to primary care surveillance is appropriate
- Long-term cardiotoxicity, second cancers, and other late effects continue to warrant attention (see long-term toxicities synthesis)
- Survivorship care plans documenting the surveillance schedule support continuity of care
Evidence table
| Time post-dx | Annual recurrence rate | Surveillance recommendation |
|---|---|---|
| Year 1–3 | ~5–10% | Exam q3–6mo, annual mammo, symptom workup |
| Year 3–5 | ~3–5% | Exam q6mo, annual mammo |
| Year 5–10 | ~1–3% | Annual exam and mammo |
| Beyond 10 years | <1% | Transition to primary care |
| BRCA carriers | Elevated | Add annual breast MRI |
| ctDNA-positive subset | Markedly elevated | Trial enrollment when available |
Open questions and active investigation
- Whether modern targeted therapy changes the case for intensive surveillance. The original "no benefit from intensive surveillance" evidence base predates pembrolizumab, ADCs, and PARP inhibitors. Whether earlier detection now enables better outcomes is being re-examined.
- ctDNA-MRD into routine practice. Whether to incorporate ctDNA monitoring into routine TNBC surveillance and what action to take on positive results are questions trials are addressing.
- Brain MRI surveillance in TNBC. Given high CNS metastasis risk, whether routine brain MRI for asymptomatic TNBC survivors would improve outcomes is debated; selected high-risk subgroups may benefit.
- Cost-effectiveness of intensive vs minimalist surveillance. Particularly relevant for ctDNA-based MRD, which is currently expensive; cost-effectiveness modeling is ongoing.
- Patient preference integration. Patients vary in their preference for intensive surveillance vs minimalist approach; shared decision-making tools could improve concordance with patient values.
- Survivorship transitions. Optimal point at which to transition surveillance from oncology to primary care varies; care models that preserve oncology access while reducing intensity are being tested.
- Liquid biopsy beyond ctDNA. Circulating tumor cells, exosomes, and methylation-based assays are alternative approaches; comparative effectiveness is being studied.
For the toxicity surveillance distinct from recurrence surveillance, see the long-term toxicities synthesis. For brain metastases — a critical TNBC recurrence pattern — see the brain metastases synthesis. For ctDNA endpoint methodology, see the endpoint design synthesis.
References
Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.
- Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–4434. doi:10.1158/1078-0432.CCR-06-3045. ↩
- Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–239. doi:10.1016/j.annonc.2020.11.007. ↩
- Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34(6):611–635. doi:10.1200/JCO.2015.64.3809. ↩
Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.